Brief: Pliant Therapeutics Announces Initiation Of BEACON-IPF, A Phase 2B Clinical Trial Of Bexotegrast In Idiopathic Pulmonary Fibrosis
09/08/2023 14:23
Aug 9 (Reuters) - Pliant Therapeutics Inc PLRX.O :
* PLIANT THERAPEUTICS ANNOUNCES INITIATION OF BEACON-IPF, A
PHASE
2B CLINICAL TRIAL OF BEXOTEGRAST IN IDIOPATHIC PULMONARY
FIBROSIS
Source text for Eikon: ID:nGNX4mV4QR
Further company coverage: PLRX.O
Recent news on Pliant Therapeutics
See all newsBrief: Pliant Therapeutics Announces Presentations At The 2026 Annual Meeting
Brief: Pliant Therapeutics Appoints David Raben, M.D., As Chief Medical Officer
RCS - Redx Pharma Limited - Redx Announces Final Audited Results
RCS - Redx Pharma Limited - Close of Series A; Strengthened Board Composition
U.S. STOCKS ON THE MOVE-Gold miners, Weave Communications, Amylyx Pharmaceuticals